Newer ALK NSCLC Options Focus on Targeting Acquired Resistance

Newer ALK+ NSCLC Options Focus on Targeting Acquired Resistance

Anne Chiang, MD, PhD, discusses the currently available treatments and ongoing research in ALK-positive non–small cell lung cancer.

Original Article: Newer ALK+ NSCLC Options Focus on Targeting Acquired Resistance

More From BioPortfolio on "Newer ALK+ NSCLC Options Focus on Targeting Acquired Resistance"